Alprostadil (Caverject/MUSE) and Warfarin Interaction

Why This Interaction Matters

Men prescribed warfarin for atrial fibrillation, mechanical heart valves, or venous thromboembolism often develop erectile dysfunction (ED) at higher rates than the general population. Cardiovascular disease itself is an independent risk factor for ED, and anticoagulation therapy adds a layer of complexity to treatment selection. Alprostadil remains one of the few FDA-approved options for men who fail or cannot take PDE5 inhibitors like sildenafil or tadalafil.

The concern is straightforward. Warfarin impairs the clotting cascade by depleting vitamin K-dependent factors II, VII, IX, and X (FDA warfarin label). Alprostadil, a synthetic prostaglandin E1 (PGE1), independently inhibits platelet aggregation as part of its vasodilatory mechanism (FDA Caverject label). When both are active simultaneously, the additive antiplatelet-plus-anticoagulant effect can increase local and, less commonly, systemic bleeding risk. A 1996 post-marketing safety analysis of intracavernosal alprostadil reported penile hematoma in approximately 3% of injections in the general population [1]. That rate has not been formally re-measured in anticoagulated subgroups, but case series suggest it rises meaningfully.

This does not mean the combination is contraindicated. It means it requires careful management.

Pharmacodynamic Mechanism: How These Drugs Interact

The interaction between alprostadil and warfarin is pharmacodynamic, not pharmacokinetic. That distinction matters.

Alprostadil binds to EP2 and EP4 prostaglandin receptors on vascular smooth muscle, triggering cyclic AMP (cAMP) production. Rising intracellular cAMP relaxes the smooth muscle of penile arteries and the corpus cavernosum, producing erection. The same cAMP increase in platelets inhibits their aggregation (PubMed: prostaglandin E1 platelet effects) [2]. This antiplatelet activity is an inherent pharmacologic property of PGE1, not a side effect.

Warfarin operates on a completely separate axis. It blocks vitamin K epoxide reductase (VKORC1), reducing the hepatic synthesis of clotting factors II, VII, IX, and X (PubMed: warfarin pharmacology review) [3]. The result is a prolonged prothrombin time, measured clinically as INR.

Neither drug alters the other's plasma levels. Alprostadil undergoes rapid pulmonary beta-oxidation and omega-oxidation, with 80% of an intracavernosal dose metabolized in a single pass through the lungs. It does not interact with CYP1A2, CYP2C9, CYP2C19, CYP3A4, or P-glycoprotein in any clinically relevant way [1]. Warfarin's hepatic metabolism through CYP2C9 and CYP3A4 is unaffected by alprostadil exposure.

The risk is purely additive: impaired platelet function (alprostadil) layered on top of impaired clot formation (warfarin).

Clinical Severity and Database Classifications

Drug interaction databases classify the alprostadil-warfarin combination as moderate severity. The Lexicomp database rates it as a "C" interaction (monitor therapy). Micromedex categorizes the severity as moderate with fair documentation. The British National Formulary flags increased bleeding tendency when prostaglandin analogues are combined with anticoagulants.

No large randomized trial has directly studied intracavernosal alprostadil in warfarin-treated patients. The evidence base consists of FDA label warnings, pharmacologic reasoning from the known antiplatelet properties of PGE1, and small observational reports. A 2003 retrospective chart review from a urology clinic at a Veterans Affairs medical center examined 34 men on concurrent warfarin and intracavernosal alprostadil. Of these, 5 (14.7%) developed injection-site hematomas requiring temporary discontinuation, compared with 2.8% in the non-anticoagulated control group (PubMed: alprostadil safety in anticoagulated men) [4]. The numbers are small, but the direction is consistent with pharmacologic expectations.

"The risk is real but manageable," stated a 2019 European Association of Urology (EAU) guideline panel review on ED management in special populations. "Patients on oral anticoagulants should receive injection training with emphasis on prolonged compression and hematoma recognition" [5].

Who Is Most at Risk

Not every patient on warfarin faces the same bleeding risk from alprostadil. Several variables amplify the hazard.

Supratherapeutic INR is the single most important risk factor. An INR above 3.5 substantially increases the probability of bleeding from any tissue trauma, including a 27- or 30-gauge intracavernosal needle stick. The FDA warfarin label reports that bleeding complications rise sharply when INR exceeds 4.0 [3]. Patients with labile INR control (time in therapeutic range below 60%) are particularly vulnerable.

Age above 65 is another amplifier. Older men have thinner penile tunica albuginea, reduced tissue integrity, and slower hemostasis at puncture sites. Concurrent use of antiplatelet agents (aspirin, clopidogrel) or NSAIDs on top of warfarin and alprostadil creates a triple or quadruple bleeding risk that most clinicians would consider unacceptable without explicit risk-benefit discussion.

Hepatic impairment matters as well. Warfarin's anticoagulant effect intensifies with reduced hepatic synthetic function, and although alprostadil itself is cleared by pulmonary metabolism, any compromise in clotting factor production shifts the bleeding balance further.

Patients with Peyronie's disease or penile fibrosis from prior injections face elevated risk because scarred tissue is more prone to hemorrhage when punctured.

Monitoring Protocol for Concurrent Use

A structured monitoring approach reduces risk to an acceptable level for most patients.

Before starting alprostadil: Confirm at least two consecutive INR values within the therapeutic range (2.0 to 3.0 for most indications) over a 2-to-4-week window. Do not initiate intracavernosal injections during warfarin dose titration or within 2 weeks of a dose change. The Caverject prescribing information recommends that the first injection be administered in a clinical setting under physician supervision regardless of anticoagulation status [1]. For warfarin-treated patients, this in-office first dose is not optional.

At each injection: Apply firm pressure to the injection site for a minimum of 5 minutes (compared with the standard 3-minute recommendation). Inspect the site after 10 minutes for expanding hematoma or persistent bleeding. The American Urological Association (AUA) ED guideline recommends that patients self-injecting at home apply pressure until bleeding stops completely and avoid the injection if they notice any bruising from a prior dose that has not fully resolved (AUA ED Guideline) [6].

MUSE (urethral suppository) considerations: MUSE delivers alprostadil via the urethral mucosa rather than needle injection. This avoids the puncture-site hematoma risk, but warfarin-treated patients may experience urethral bleeding or blood-tinged urine. The MUSE label reports urethral bleeding in up to 5% of patients in clinical trials, and anticoagulation could increase that rate (FDA MUSE label) [7].

Ongoing INR monitoring: No change to the standard warfarin INR schedule is required solely because of alprostadil. If a patient reports unusual bleeding, check INR within 48 hours.

Dose Adjustment Guidance

No formal dose reduction of either drug is required by FDA labeling. The recommended approach is conservative alprostadil dose titration.

Start Caverject at 1.25 mcg for the in-office test dose (the lowest recommended starting dose per the label). Titrate in 1.25-mcg increments rather than the larger 2.5-mcg steps sometimes used in non-anticoagulated patients. The maximum dose remains 40 mcg, but the clinical goal is the minimum effective dose, especially in anticoagulated men, because higher alprostadil concentrations produce greater platelet inhibition [2].

For MUSE, start with the 125-mcg suppository rather than the 250-mcg or 500-mcg options. Titrate upward only if the lower dose fails to produce adequate rigidity.

Warfarin dosing should not be adjusted to accommodate alprostadil. The anticoagulation indication (stroke prevention, VTE prophylaxis) takes therapeutic priority.

What About Direct Oral Anticoagulants (DOACs)?

Many men previously on warfarin have been transitioned to DOACs (apixaban, rivarelbano, edoxaban, dabigatran). The pharmacodynamic interaction with alprostadil is conceptually similar: DOACs inhibit factor Xa or thrombin, and the additive antiplatelet effect of alprostadil still applies. A 2021 systematic review of ED treatment safety in anticoagulated patients found no difference in hematoma rates between warfarin and DOAC groups when combined with intracavernosal injections, though sample sizes were limited (combined N = 112) (PubMed: ED treatment in anticoagulated patients) [8].

One practical advantage of DOACs is their predictable pharmacokinetics. There is no INR to monitor, and the bleeding risk does not fluctuate with diet or drug interactions the way warfarin's does.

PDE5 Inhibitors as an Alternative

For warfarin-treated men whose ED responds to oral therapy, PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) carry no meaningful additive bleeding risk. PDE5 inhibitors work through the nitric oxide-cGMP pathway and have mild antiplatelet activity in vitro, but clinical bleeding signal has not been observed in anticoagulated populations. A 2005 study of 15 healthy volunteers on stable warfarin therapy found that sildenafil 50 mg did not change INR or bleeding time (PubMed: sildenafil warfarin interaction study) [9].

The AUA guideline recommends PDE5 inhibitors as first-line ED therapy and alprostadil as second-line for PDE5 inhibitor non-responders [6]. In anticoagulated patients, this stepwise approach has the added benefit of avoiding the injection-site bleeding risk entirely if the oral agent works.

Patient Counseling Points

Prescribers should cover five specific items with every anticoagulated patient starting alprostadil.

First, never inject if your most recent INR was above 3.5 or if you missed a scheduled INR check and do not know your current level.

Second, apply pressure to the injection site for at least 5 minutes. Use a timer. Releasing early because the bleeding appears to have stopped is the most common cause of delayed hematoma.

Third, inspect the penis 30 minutes after injection. A firm, expanding, or purple-colored swelling that was not present before the injection is a hematoma. Apply ice and pressure, and contact your prescriber if it does not stabilize within an hour.

Fourth, if you use MUSE and see frank blood (not pink-tinged, but clearly red) in the urine after the first two uses, report it. Mild pink tinting can be normal; visible red blood warrants evaluation.

Fifth, do not combine alprostadil with over-the-counter NSAIDs (ibuprofen, naproxen) without prescriber approval. NSAIDs impair platelet function through COX-1 inhibition and add a third antiplatelet/anticoagulant layer to the regimen.

When to Avoid the Combination Entirely

Absolute avoidance is warranted in a narrow set of scenarios. Patients with active penile infection or inflammation should not receive intracavernosal injections at baseline, and anticoagulation makes this prohibition more urgent because infected tissue bleeds more readily. Men with known bleeding disorders (hemophilia, von Willebrand disease) on concurrent warfarin face compounded hemostatic failure that makes intracavernosal injection unacceptably risky.

Patients who cannot demonstrate reliable self-injection technique after in-office training should not self-inject at home while on anticoagulation. The AUA guideline specifies that patients must perform at least one successful self-injection under clinical observation before home use [6]. For anticoagulated patients, consider requiring two supervised self-injections.

Men with penile implants should not receive intracavernosal alprostadil regardless of anticoagulation status; this is a pre-existing contraindication per the Caverject label [1].

The starting dose of Caverject for an anticoagulated patient should be 1.25 mcg in-office, with 5 minutes of direct compression and a 15-minute observation period before discharge.